Short Interest in BioNTech SE (NASDAQ:BNTX) Decreases By 16.5%

BioNTech SE (NASDAQ:BNTX) was the recipient of a significant drop in short interest in August. As of August 31st, there was short interest totalling 2,580,000 shares, a drop of 16.5% from the August 15th total of 3,090,000 shares. Based on an average daily volume of 704,700 shares, the short-interest ratio is presently 3.7 days. Approximately 1.1% of the shares of the stock are short sold.

BioNTech Stock Performance

Shares of BioNTech stock opened at $123.40 on Monday. The stock’s fifty day moving average price is $87.28 and its 200-day moving average price is $89.66. BioNTech has a 12 month low of $76.53 and a 12 month high of $125.41. The firm has a market cap of $29.34 billion, a P/E ratio of 246.80 and a beta of 0.23. The company has a current ratio of 7.54, a quick ratio of 7.40 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Monday, August 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.02) by ($1.34). The business had revenue of $128.70 million for the quarter, compared to analysts’ expectations of $134.98 million. BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The business’s quarterly revenue was down 23.3% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.86) earnings per share. On average, equities research analysts expect that BioNTech will post -2.8 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Candriam S.C.A. increased its position in shares of BioNTech by 261.2% during the second quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock worth $46,526,000 after purchasing an additional 418,695 shares in the last quarter. Neuberger Berman Group LLC purchased a new position in BioNTech during the 4th quarter worth $1,562,000. US Bancorp DE increased its position in BioNTech by 420.7% during the 4th quarter. US Bancorp DE now owns 28,614 shares of the company’s stock valued at $3,020,000 after buying an additional 23,119 shares in the last quarter. Goldman Sachs Group Inc. increased its position in BioNTech by 17.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 182,878 shares of the company’s stock valued at $19,301,000 after buying an additional 26,777 shares in the last quarter. Finally, Harding Loevner LP purchased a new stake in BioNTech in the fourth quarter valued at about $410,984,000. Institutional investors own 15.52% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on BNTX shares. Jefferies Financial Group increased their price target on BioNTech from $90.00 to $96.00 and gave the company a “hold” rating in a research note on Friday. Hsbc Global Res upgraded BioNTech from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 2nd. HC Wainwright reissued a “buy” rating and issued a $113.00 target price on shares of BioNTech in a report on Tuesday, August 27th. JPMorgan Chase & Co. decreased their price objective on BioNTech from $94.00 to $91.00 and set an “underweight” rating on the stock in a research report on Thursday, August 15th. Finally, HSBC upgraded shares of BioNTech from a “hold” rating to a “buy” rating in a research report on Friday, August 2nd. One analyst has rated the stock with a sell rating, six have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, BioNTech has an average rating of “Hold” and a consensus target price of $108.00.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.